ASG Stock Overview
Through its subsidiary, Aurora Spine, Inc., engages in the development and distribution of minimally invasive interspinous fusion systems and devices in Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Aurora Spine Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.45 |
| 52 Week High | CA$0.47 |
| 52 Week Low | CA$0.22 |
| Beta | 0.61 |
| 11 Month Change | 20.27% |
| 3 Month Change | 58.93% |
| 1 Year Change | 7.23% |
| 33 Year Change | 23.61% |
| 5 Year Change | 64.81% |
| Change since IPO | -67.04% |
Recent News & Updates
Aurora Spine Corporation (CVE:ASG) Soars 26% But It's A Story Of Risk Vs Reward
Oct 19
We Think Aurora Spine (CVE:ASG) Has A Fair Chunk Of Debt
Oct 16Aurora Spine Corporation's (CVE:ASG) Subdued P/S Might Signal An Opportunity
Aug 14Recent updates
Aurora Spine Corporation (CVE:ASG) Soars 26% But It's A Story Of Risk Vs Reward
Oct 19We Think Aurora Spine (CVE:ASG) Has A Fair Chunk Of Debt
Oct 16Aurora Spine Corporation's (CVE:ASG) Subdued P/S Might Signal An Opportunity
Aug 14We Think Shareholders May Want To Consider A Review Of Aurora Spine Corporation's (CVE:ASG) CEO Compensation Package
Jun 19Is Aurora Spine (CVE:ASG) A Risky Investment?
May 29There Is A Reason Aurora Spine Corporation's (CVE:ASG) Price Is Undemanding
Mar 19Would Aurora Spine (CVE:ASG) Be Better Off With Less Debt?
Oct 15Why Investors Shouldn't Be Surprised By Aurora Spine Corporation's (CVE:ASG) Low P/S
Aug 11Here's Why Aurora Spine (CVE:ASG) Can Afford Some Debt
May 01Aurora Spine (CVE:ASG) Is Making Moderate Use Of Debt
Dec 22Would Aurora Spine (CVE:ASG) Be Better Off With Less Debt?
Aug 23Health Check: How Prudently Does Aurora Spine (CVE:ASG) Use Debt?
May 04Health Check: How Prudently Does Aurora Spine (CVE:ASG) Use Debt?
Dec 23Aurora Spine (CVE:ASG) Is Making Moderate Use Of Debt
Jun 11A Look At The Intrinsic Value Of Aurora Spine Corporation (CVE:ASG)
Feb 26Is Aurora Spine (CVE:ASG) A Risky Investment?
Nov 19
Shareholder Returns
| ASG | CA Medical Equipment | CA Market | |
|---|---|---|---|
| 7D | -2.2% | 1.8% | 1.3% |
| 1Y | 7.2% | 5.5% | 23.1% |
Return vs Industry: ASG exceeded the Canadian Medical Equipment industry which returned 5.5% over the past year.
Return vs Market: ASG underperformed the Canadian Market which returned 23.1% over the past year.
Price Volatility
| ASG volatility | |
|---|---|
| ASG Average Weekly Movement | 13.3% |
| Medical Equipment Industry Average Movement | 13.2% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 17.8% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: ASG's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: ASG's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | n/a | Trent Northcutt | www.aurora-spine.com |
Aurora Spine Corporation, through its subsidiary, Aurora Spine, Inc., engages in the development and distribution of minimally invasive interspinous fusion systems and devices in Canada. The company offers interspinous process lumbar fusion devices, such as the ZIP, ZIP ULTRA, ZIP LP, and ZIP-51 for patients suffering from degenerative disc diseases; and Ti-Coated polyether ether ketone interbody cages, which provide spacing and stability between the vertebrae while bone grows to complete the fusion process. It also provides sterile-packed titanium plasma spray coated spinal infusion implants for bone growth, as well as interbody products, such as EOS, VOX, Echo, Echo SD, and EchoXL for the lumbar section of the spine, and discovery for cervical procedures.
Aurora Spine Corporation Fundamentals Summary
| ASG fundamental statistics | |
|---|---|
| Market cap | CA$34.84m |
| Earnings (TTM) | -CA$888.84k |
| Revenue (TTM) | CA$23.64m |
1.5x
P/S Ratio-38.8x
P/E RatioIs ASG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ASG income statement (TTM) | |
|---|---|
| Revenue | US$16.90m |
| Cost of Revenue | US$6.70m |
| Gross Profit | US$10.21m |
| Other Expenses | US$10.84m |
| Earnings | -US$635.51k |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0082 |
| Gross Margin | 60.39% |
| Net Profit Margin | -3.76% |
| Debt/Equity Ratio | 53.1% |
How did ASG perform over the long term?
See historical performance and comparison